ProCE Banner Series

Beyond Barriers: Managed Care Approaches to Ensure Equitable and Timely Access to BCMA-Directed Therapy in Multiple Myeloma

Join us in New Orleans or via simulcast for this live, interactive 1.5-hour CE-certified program led by pharmacy experts discussing optimal managed care strategies to incorporate BCMA-directed therapy in multiple myeloma.

  ACPE-P
Who Should Attend

The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with multiple myeloma and pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice and managed care.

All Events

Beyond Barriers: Managed Care Approaches to Ensure Equitable and Timely Access to BCMA-Directed Therapy in Multiple Myeloma

Upcoming Events

April

17

2024

11:30 AM - 1:30 PM Central Time (CT)

In-person

Ernest N. Morial Convention Center, 900 Convention Center Blvd, New Orleans, Louisiana 70130

12:00 PM - 1:30 PM Central Time (CT)

Virtual

Faculty

ProCE Banner Faculty
Rebecca Gonzalez, PharmD, BCOP

Blood and Marrow Transplant and Cellular Immunotherapy Clinical Pharmacist
Moffitt Cancer Center
Tampa, Florida

ProCE Banner Faculty
Melissa Pozotrigo, PharmD, BCOP

Senior Clinical Oncology Pharmacist
OncoHealth
Atlanta, Georgia

Topics

Multiple Myeloma

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Myelofibrosis.

Target Audience
The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with multiple myeloma and pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice and managed care.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess the role of BCMA and BCMA-targeted therapies in R/R MM 
  • Evaluate efficacy and safety evidence for BCMA-targeted therapies in patients with R/R MM and the impact of therapeutic choices in a managed care setting
  • Apply recommendations to identify and manage treatment-related AEs in patients treated with BCMA-targeted therapies for R/R MM 
  • Integrate best practices in managed care with recent updates on BCMA-targeted therapies to optimize equitable access and informed formulary decisions for R/R MM patients.

Accreditation

CE Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-24-004-L01-P has been assigned to this live application-based activity (initial release date 4/17/2024). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC In partnership with Clinical Care Options, LLC

Supported by an educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.